News | June 08, 2024
Borosil Scientific debuts on stock exchange
This strategic decision will unlock significant value for our scientific and industrial products business
This strategic decision will unlock significant value for our scientific and industrial products business
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Greg was also central to the planning, design, and construction of this facility
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Subscribe To Our Newsletter & Stay Updated
